The B2B Podcast Index
Index
All categories
MarketingSalesSaaSFinanceHROpsLeadershipCustomer SuccessAI & DataProductStartups & FoundersRevOpsEngineering & DevTools
MethodologySubmit
Best of:MarketingSalesSaaSFinanceHROpsLeadershipCustomer SuccessAI & DataProductStartups & FoundersRevOpsEngineering & DevTools
An independent project byFame
SearchBest episodesGuestsInsightsMethodologySubmit a podcast
Index/Leadership/The CEO Diary with Fexingo
The CEO Diary with Fexingo artwork

How Novo Nordisk Conquered Obesity and the Weight Loss Drug Market

The CEO Diary with Fexingo · 2026-07-12 · 10 min

0:00--:--

Topics in this episode

OzempicNovo NordiskGLP-1Wegovyweight loss drugs

Episode notes

In this episode, Lucas and Luna dive into the story of Novo Nordisk, the Danish pharmaceutical giant that has become the world's most valuable company in Europe by dominating the weight loss drug market with Ozempic and Wegovy. They explore how CEO Lars Fruergaard Jørgensen navigated supply shortages, regulatory hurdles, and public scrutiny, while maintaining a purpose-driven culture. The hosts discuss the company's unconventional origins as a insulin maker, its shift into GLP-1 drugs, and the strategic decisions that led to a market cap exceeding $600 billion. Along the way, they examine the ethical dilemmas of pricing, access, and the thin line between treatment and lifestyle drug. A compelling look at leadership, innovation, and the business of changing global health. #NovoNordisk #Ozempic #Wegovy #GLP1 #WeightLossDrugs #Obesity #Pharma #Business #CEO #LarsFruergaardJorgensen #Leadership #Denmark #Healthcare #Innovation #SupplyChain #FexingoBusiness #BusinessPodcast #TheCEODiary Keep every episode free: buymeacoffee.com/fexingo

Related episodes across the Index

Other episodes covering the same guests and topics, from across The B2B Podcast Index.

  • Targeting the Root Causes of Metabolic Disease w/ Bob Geho, Founder & CEO, DiasomeCareTalk: Healthcare. Unfiltered. · on GLP-194 / 100
  • “Every Time You Walk in the Room, You’re Being Evaluated” - Ricky Hopson, Catalent Group President and Chief of StaffExecutiveland · on Novo Nordisk76 / 100
  • How Deepak Datta Turned Medical Tourism Into a Global Healthcare BusinessMarket Movers · on Ozempic65 / 100
  • The GLP-1 Economy: How New Prescriptions Are Reshaping MarketsThe Important Part: Investing with Liz Thomas · on Ozempic63 / 100
  • The Bottom Line Catch Up | Ep. 1 | Tax Season, Transitions, and the Peptide WaveThe Bottom Line Pharmacy Podcast · on GLP-150 / 100
  • Helping People Live Better: Marketing's Role in the Future of Health with Google, Novo Nordisk and BayerThe CMO Podcast · on Novo Nordisk49 / 100

More from The CEO Diary with Fexingo

All episodes →
  • How the CEO of Seven-Eleven Japan Rethought Convenience54 / 100
  • How Patagonia Proved Purpose Pays Dividends
  • How Satya Nadella Changed Microsofts Culture First
  • How the CEO of a Family Firm Kept It Private Through a Century of Change
  • How the CEO of Nvidia Sped Up the Chip Race
Explore the best B2B Leadership podcasts →
All The CEO Diary with Fexingo episodes →